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Introduction 
Acute heart failure (AHF) due to peripartum cardiomyopathy (PPCM) provides a challenge for 
treating physicians. Moreover, in patients still pregnant, therapeutic interventions need always to consider 
the health of both the mother and the foetus. Especially challenging are severe forms of PPCM, as the 
mortality of these women is quite high. The use of inotropic drugs and mechanical circulatory support 
devices may be necessary in the initial phase of severe forms of acute PPCM. Many patients, after initial 
stabilization, recover LV function.
1-3
 Unfortunately, some patients need further mechanical circulatory 
support or urgent heart transplantation despite maximal therapy. In addition, the time frame and extent of 
recovery are unpredictable, and patients may suffer from cardiac arrest due to ventricular fibrillation in 
the first months after diagnosis.
4
 The clinical course may be further aggravated by atrial and/or 
ventricular thrombus formation with subsequent cardio‐embolic complications.  
 
As evidence‐based data from randomized clinical trials are scarce, in this practical guidance we 
summarize recent data and clinical experience in the treatment of patients with severe acute PPCM to 
help physicians in the diagnosis, acute treatment, and long‐term management of these young critically ill 
patients. 
Definition and pathophysiology 
The Working Group on PPCM of the Heart Failure Association (HFA) of the European Society of 
Cardiology (ESC) recently proposed a new simplified definition of PPCM as an idiopathic 
cardiomyopathy frequently presenting with heart failure secondary to LV systolic dysfunction (LVEF 
<45%) towards the end of pregnancy or in the months following delivery, if no other cause of heart 
failure is found.
1 
Since no specific test to confirm PPCM exists, it remains a diagnosis of exclusion. In 
particular, aggravation of pre‐existing heart disease by pregnancy‐mediated haemodynamic changes 
should be differentiated from PPCM.  
 
The pathophysiology of PPCM remains poorly understood. The current status of knowledge of the 
pathophysiological mechanisms of PPCM has been published elsewhere.
3
 A ‘two‐hit’ model of 
angiogenic imbalance in the heart during the peripartal period has recently been proposed, combining 
systemic antiangiogenic signals during late pregnancy and host susceptibility through insufficient local 
proangiogenic defences in the heart.
1-3, 5
 Angiogenic imbalance can further be triggered by oxidative 
stress activating cathepsin D, a protease responsible for the cleavage of the nursing hormone prolactin 
into the angiostatic and proapoptotic 16 kDa subfragment.
4, 6
 
Clinical presentation of acute peripartum cardiomyopathy 
Most patients admitted with PPCM present typical symptoms of AHF associated with signs of 
congestion. Because early signs and symptoms of heart failure in PPCM patients may mimic 
physiological changes occurring during/after pregnancy, delayed diagnosis may occur. The differential 
diagnosis of acute PPCM includes myocarditis, pre‐existing cardiomyopathy, valve disease, or congenital 
heart disease. In the case of cardiogenic shock, pregnancy‐associated myocardial infarction, pulmonary 
embolism, and amniotic liquid embolism should be immediately ruled out to provide adequate care (Table 
1).  
  
Table 1. Peripartal acute dyspnoea: differential diagnosis of acute peripartum cardiomyopathy 
 
PPCM 
Pre‐existing 
CMP,valve disease 
orcongenital 
heartdisease 
Pregnancy‐
associatedmyocardial 
infarction 
Pulmonary 
embolism/amniotic 
liquid embolism 
Myocarditis 
      
History Most commonly 
post‐partal onset 
of dyspnoea 
Earlier onset 
(during second 
trimester) 
Sometimes family 
history 
Retrosternal chest pain, 
abdominal discomfort, 
nausea 
Pleuritic chest pain Infection 
Biomarkers Elevated 
natriuretic 
peptides 
Elevated natriuretic 
peptides 
Elevated troponin Elevated D‐dimer, 
troponin, natriuretic 
peptides 
Elevated troponin 
Possibly. elevated 
natriuretic peptides 
Echocardiography Left and/or right 
ventricular 
dysfunction 
Evidence of pre‐
existing valve 
disease or 
congenital defect 
Regional 
hypokinesis/akinesis 
RV dysfunction, 
elevated RV pressure, 
McConnell's sign 
Regional or general 
hypokinesis 
Additional tests Consider MRI Consider MRI 
Consider genetic 
test 
Coronary angiography CT‐scan or. V/Q 
scintigraphy; consider 
angiography 
MRI 
Consider myocardial 
biopsy 
      
 
CMP, cardiomyopathy; MRI, magnetic resonance imaging; PPCM, peripartum cardiomyopathy; RV, right ventricular. 
 
Evaluation of acute peripartum cardiomyopathy 
As for any AHF, initial evaluation of patients with suspected acute PPCM includes two parts, which 
should be performed simultaneously to allow timely diagnosis and treatment delivery: evaluation of 
cardiopulmonary distress; and confirmation of the diagnosis with additional tests. 
Evaluation of cardiopulmonary distress 
Evaluation of cardiopulmonary distress is crucial because it will influence subsequent treatment and 
patients' allocation. The presence of criteria defining cardiopulmonary distress should lead to intensive 
cardiac care unit admission: haemodynamic instability (systolic blood pressure <90 mmHg, heart rate 
>130 b.p.m. or <45 b.p.m.), respiratory distress (respiratory rate >25/min; peripheral oxygen saturation 
<90%), or signs of tissue hypoperfusion with abnormal cellular oxygen metabolism (increased blood 
lactate >2.0 mmol/L; low central–venous oxygen saturation <60%, if available; altered mental state; cold, 
clammy, mottled skin; oliguria <0.5 mL/kg/h).
1, 7
 
Confirmation of the diagnosis 
Since PPCM is a diagnosis of exclusion, several additional tests should be performed (see below). 
This should not delay the start of treatment, which should be instituted as soon as AHF is confirmed. 
 
An ECG should be performed in all patients with suspected PPCM as it has high negative predictive 
value and might help in identifying the cardiac origin of dyspnoea. Indeed, despite the fact that no 
specific ECG pattern for PPCM seems to exist, at initial evaluation, the ECG is rarely normal and 
repolarization abnormalities are common.
4, 8, 9
 Patients with acute PPCM usually have elevated plasma 
concentrations of natriuretic peptides.
10, 11
 Measurement of natriuretic peptides may help during screening 
for identifying a cardiac origin of dyspnoea, although it does not help in the differentiation of PPCM from 
other cardiomyopathies. More specific biomarkers would be helpful to allow a faster and more reliable 
diagnosis of PPCM, but these are yet to be adequately defined. Echocardiography is indicated as soon as 
possible, in all cases of suspected PPCM to confirm the diagnosis, assess concomitant or pre‐existing 
cardiac disease, exclude complications of PPCM (e.g. LV thrombus), and obtain prognostic information.  
 
Cardiac magnetic resonance imaging (MRI) is not routinely needed, but can be performed after 
stabilization in cases where additional information, not available with echocardiography, is needed. 
However, administration of gadolinium to assess late enhancement should be avoided until after delivery, 
unless absolutely necessary. Endomyocardial biopsy does not add any diagnostic or prognostic 
information in the case of PPCM but can be used to exclude acute myocarditis after delivery. Only a few 
PPCM cases have been related to myocarditis so far,
12
 but myocarditis may underlie cases of dilated 
cardiomyopathies and AHF that can occur or worsen during pregnancy, and specific immunosuppressive 
or immune‐modulatory treatments may be helpful for some forms of myocarditis.13 
Management of acute peripartum cardiomyopathy 
The management of heart failure around pregnancy is challenging (Box 1), and, in the absence of 
evidence‐based data, the initial management of patients with PPCM is similar to the treatment of AHF of 
other aetiologies.
14, 15
 Interdisciplinary approaches of cardiologists, intensivists, obstetricians, 
neonatologists, anaesthetists, and cardiac surgeons are necessary in cases of severe AHF. Pre‐specified 
protocols of interdisciplinary work‐up of these patients are helpful (Figure 1).16 Timely diagnosis and 
treatment delivery are crucial. Figure 2 summarizes the recommended treatment algorithm for patients 
with acute PPCM. Of note, the initial treatment of patients with severe forms of acute PPCM is 
significantly different from that of stable patients.  
BOX 1. Peculiarities in the management of acute heart failure caused by peripartum 
cardiomyopathy  
 
 Multidisciplinary approach with focus on health of mother and foetus. 
 Avoidance of heart failure (HF) drugs with foetal toxicity during pregnancy (i.e. ACE 
inhibitors/ARBs, mineralocorticoid receptor antagonists) and breastfeeding; thereafter standard 
HF therapy. 
 Consideration of bromocriptine (2.5 mg twice daily for 2 weeks, followed by 2.5 mg per day for 
6 weeks) in addition to standard HF therapy. 
 Anticoagulation with heparin to avoid cardio‐embolic complications in patients with LVEF 
≤35% or treated with bromocriptine (if no contraindication exists). 
 In the case of cardiogenic shock, consideration of levosimendan (0.1 µg/kg/min for 24 h) instead 
of catecholamines as first‐line inotropic drug. Early transfer to experienced centre. Early 
evaluation of mechanical circulatory support according to the centre's experience. 
 Prevention of sudden cardiac death, early consideration of wearable cardioverter‐defibrillator 
devices in patients with LVEF ≤35%. 
 
 
 
Figure 1. Example of prespecified protocol of interdisciplinary work‐up for acute heart failure (AHF) during pregnancy (modified 
from the protocol of the Medical School Hannover). 
 
 
 
Figure 2. Algorithm for initial management. BB, beta‐blocker; HF, heart failure; HR, heart rate; NIV, non‐invasive ventilation; 
PDA, peridural anaesthesia; RR, respiratory rate; SBP, systolic blood pressure; SpO2, peripheral oxygen saturation; WCD, wearable 
cardioverter‐defibrillator.
Initial management of acute peripartum cardiomyopathy with cardiopulmonary distress and/or 
haemodynamic instability 
Patients with signs of cardiopulmonary distress and/or circulatory shock need rapid and more 
aggressive therapy and should be admitted to the intensive cardiac care unit. Initial therapy includes five 
main elements: optimization of the preload; optimization of oxygenation; restoration of haemodynamics 
with inotropes and/or vasopressors; urgent delivery if heart failure occurs during pre‐partum; and 
consideration of adjunctive therapies with bromocriptine (2.5 mg twice daily for 2 weeks followed by 2.5 
mg per day for 6 weeks). 
 
Optimization of preload includes, depending on the clinical scenario, administration of fluids or 
diuretics. If there is no sign of overt fluid overload, a fluid challenge (250–500 mL over 15–30 min) is 
recommended, especially in patients with intravascular depletion secondary to peripartal blood loss or 
overaggressive diuretic therapy. In the presence of signs of congestion, intravenous diuretics should be 
administered. In patients with systolic blood pressure >110 mmHg, intravenous vasodilators (e.g. nitrates) 
should be started. 
 
At the same time, oxygenation should be optimized (target peripheral oxygen saturation, 
SpO2 > 95%). Non‐invasive ventilation (NIV) reduces respiratory distress and may decrease intubation 
and mortality rates.
17
 Intubation with mechanical ventilation should be considered in the case of altered 
mental state or persistent hypoxaemia.  
 
In the presence of signs of cardiogenic shock, haemodynamics should be rapidly restored to avoid 
irreversible organ damage. Inotropes and vasopressors may be considered, although the use of 
catecholamines is associated with adverse effects in patients with advanced heart failure or cardiogenic 
shock.
18, 19
 Experimental evidence and clinical experience suggest that catecholamines such as 
dobutamine are less favourable in PPCM patients due to metabolic compromise.
20
 Therefore, 
catecholamines should be avoided whenever possible or used only with extreme caution. Levosimendan, 
in contrast to dobutamine and adrenaline, does not increase myocardial oxygen demand and may be 
considered as the preferred inotropic agent as continuous infusion of 0.1 µg/kg/h for 24 h without an 
initial loading dose (bolus) for patients with severe PPCM.
21
 A recent small study including 28 patients 
showed that the use of levosimendan in patients with PPCM induced rapid haemodynamic recovery and 
profound decongestive effects
.22
 In case levosimendan is unavailable, dobutamine is the other option, 
while adrenaline should be avoided. As for other causes of shock, noradrenaline should be the first‐line 
vasopressor.  
 
Patients with haemodynamic instability despite treatment should undergo urgent delivery irrespective 
of gestation duration. Caesarean section with combined spinal and epidural analgesia and involvement of 
an experienced interdisciplinary team are recommended. 
 
The administration of adjunctive therapies with the prolactin blocker bromocriptine has shown 
promising results in several case series and in a small proof‐of‐concept study,23 and should be considered 
for patients with cardiopulmonary distress. The starting dose of bromocriptine is usually 2.5 mg twice 
daily, but an increased dose may be necessary to lower prolactin levels in selected cases (see below).  
As thrombo‐embolic events have been reported during the use of bromocriptine (albeit mostly at 
higher dosages), bromocriptine treatment should always be accompanied by at least prophylactic 
anticoagulation with heparin.
24
 Anticoagulation with heparin should also be started in all patients with 
acute PPCM and severely reduced LV systolic function (LVEF ≤35%). Indeed, the combination of 
reduced EF and the procoagulant activity during the peripartal phase exposes patients to a clinically 
important risk of cardio‐embolic events.  
  
In general, patients with severe distress should be transferred early to an experienced centre whenever 
possible. For patients with persistent haemodynamic instability despite medical treatment, mechanical 
circulatory support should be considered (see below). 
Advanced management of severe acute peripartum cardiomyopathy 
Implantation of a mechanical circulatory support should be considered early as a rescue therapy in 
patients who cannot be stabilized with medical therapy alone. 
 
If necessary, a device for temporary support should be implanted in the acute phase, either as ‘bridge‐
to‐recovery’, if ventricular function improves during the subsequent days and weaning can be achieved, 
or as ‘bridge‐to‐bridge’, if haemodynamic impairment persists and circulatory support has to be ensured 
by switching to a more durable (and usually more invasive) device. Because of the higher proportion of 
patients with at least partial recovery of ventricular function compared with other cardiomyopathies, an 
initial ‘bridge‐to‐transplantation’ strategy is seldom necessary. 
 
Since several devices exist, and there is little evidence about which device should be preferred;
25 
we 
provide here an overview of some devices based on experts' opinion.  
 
For the choice of the initial device, several factors should be taken into account (needed 
haemodynamic support, periprocedural risks, costs), but the oxygenation status of the patient plays a 
central role. If the patient is adequately oxygenated, percutaneous [e.g. intra‐aortic balloon pump (IABP), 
Impella®] or surgical (e.g. CentriMag®, AbiomedBVS 5000®) devices can be used to restore circulation. 
In contrast, in the presence of impaired oxygenation, other devices with integrated oxygenation should be 
used [e.g. TandemHeart®, veno‐arterial extracorporeal membrane oxygenation (ECMO)]. Most 
importantly, as the treatment of patients on mechanical circulatory support is very challenging, the choice 
of the device should also consider the local availability and the experience of the involved care team 
(physicians, nurses, and perfusionists). 
 
Percutaneous devices offer the advantage of fast and easier placement and removal without the need 
for open surgery, but complications related to the access site (bleeding, infection, ischaemic limbs) are 
not uncommon. An IABP provides less haemodynamic support compared with other devices, but on the 
other hand is easily placed and needs less strict anticoagulation. Given the negative results of the IABP‐
SHOCK II trial and the lack of data in PPCM, the value of this device in patients with severe PPCM is 
uncertain, although it is used in selected cases by some centres.
26 
The Impella® rotary pump is an 
alternative percutaneous device for temporary support. It is inserted percutaneously from the femoral 
artery and is placed in the left ventricle through the aortic valve. Depending on the model, it provides a 
higher degree of haemodynamic support compared with IABP (up to 5 L/min) but is associated with 
haemolysis and, especially in the context of PPCM, where a procoagulant state is frequent, a stricter 
anticoagulation regime than for IABP is needed.
27
 In a small trial in patients with cardiogenic shock 
complicating myocardial infarction, there was no difference in terms of survival between IABP and 
Impella®.
28
 Clinical experience in several PPCM patients with the Impella 3.5 device suggests effective 
LV support over up to 7–10 days when used as bridge‐to‐recovery in most patients. The marked decrease 
in the need for catecholamines may importantly contribute to the beneficial outcome observed in several 
patients (Figure 3). The TandemHeart® device offers similar haemodynamic support to Impella® (up to 
5 L/min) with additional improvement in oxygenation. The placement of this device is performed 
percutaneously in the catheterization laboratory but it requires a more complex placement with atrial 
trans‐septal puncture. No evidence of improved outcomes in patients with cardiogenic shock receiving 
TandemHeart® compared with IABP exists.
29, 30
 
  
 
 
 
Figure 3. Example of the management of a peripartum cardiomyopathy (PPCM) patient with cardiogenic shock in the intensive care 
unit (ICU). The figure depicts the management of a patient with newly diagnosed PPCM in cardiogenic shock with severely reduced 
EF requiring mechanical ventilation and high dose vasopressor (norepinephrine), and inotropic support (dobutamine) at the acute 
presentation. Upon referral to the Acute and Advanced Heart Failure Unit of Medical School Hannover, temporary circulatory 
support with the Impella CP® rotary pump was initiated with concurrent invasive haemodynamic monitoring including pulmonary 
artery wedge pressure (PAWP) by means of a Swan–Ganz catheter. Note the decline of catecholamine dosage and PAWP after 
insertion of the Impella CP® rotary pump. Additionally, two cycles of 24‐h infusion of levosimendan were administered with an 
interval of 1 week, and diuretic therapy was given throughout the intensive care. After 10 days, when haemodynamic stabilization 
was achieved, the patient could be extubated and standard heart failure therapy including an ACE inhibitor (later replaced by an 
ARB due to cough), mineralocorticoid receptor antagonist, and beta‐blocker was established. Heart rate reduction with ivabradine 
was initiated early during ICU course. The patient was treated with a wearable cardioverter‐defibrillator for 6 months and had an 
uneventful course; EF showed a partial recovery during the following 6 months. 
Extracorporeal membrane oxygenation with veno‐arterial cannulation offers the maximal available 
haemodynamic effect with biventricular support and additional improvement in oxygenation.
31
 As 
increased prolactin levels during ECMO treatment have been reported, which may be specifically 
detrimental in patients with PPCM,
32 
effective suppression of prolactin under sequential measurements of 
prolactin levels could be considered in this particular situation with bromocriptine doses up to 10 mg 
twice daily.  
 
After the initial phase, if no weaning from mechanical circulatory support can be achieved after a 
maximum of 7–10 days, a switch to a durable device should be planned. As for temporary support, 
several devices exist and little evidence is available to guide the choice of the optimal device. Special 
attention should be paid to right ventricular function. In the presence of impaired right ventricular 
function, a biventricular assist device (BiVAD or total artificial heart) may be chosen (e.g. Berlin Heart 
EXCOR®). Alternatively, several strategies of transient right ventricular support in patients after left 
ventricular assist device (LVAD) implantation have been adopted in different centres (e.g. veno‐arterial 
ECMO, Impella® RP, or similar). In patients with preserved right ventricular function, LVADs should be 
preferred. The most commonly used devices are the continuous‐flow axial (HeartMate II®) and 
centrifugal (HeartWare®) LVADs which have shown promising results in patients with end‐stage heart 
failure.
33-35
 Given the high likelihood of at least partial recovery of ventricular function in PPCM, 
temporary devices should always be the preferred initial strategy. Cardiac transplantation is reserved for 
patients where mechanical circulatory support is not possible or satisfactory ventricular recovery after 6–
12 months is not achieved. Post‐transplant outcomes in women with PPCM appear to be worse than in 
other recipients: in particular, women with PPCM show higher mortality, a higher incidence of rejection 
with shorter graft survival, and higher rates of re‐transplantation.36 
Management of acute peripartum cardiomyopathy without cardiopulmonary distress 
The initial treatment of patients with confirmed PPCM without cardiopulmonary distress depends on 
the time point of onset. Patients who present after delivery should be treated according to the ESC 
guidelines for heart failure.
37 
For patients presenting during pregnancy, joint cardiac and obstetric care in 
observance of the ESC guidelines for management of cardiovascular diseases in pregnancy is 
recommended.
38
 
 
During pregnancy, ACE inhibitors, ARBs, and renin inhibitors are contraindicated because of foetal 
toxicity. Hydralazine and nitrates can be used instead. After delivery, ACE inhibitors can be started, but 
during breastfeeding captopril or enalapril should be preferred. Despite an increased risk of foetal growth 
restriction, beta‐blockers are indicated in all patients in stable condition, with metoprolol succinate being 
the preferred agent.
38,39
 Mineralocorticoid receptor antagonists (MRAs) should be avoided during 
pregnancy and lactation, but should be started afterwards in stable patients. Diuretics should be 
administered with caution during pregnancy as they may impair perfusion of the placenta. 
Recommendations for drug use during pregnancy and breastfeeding are summarized in table 21 of the 
ESC guidelines for management of cardiovascular diseases in pregnancy.
38
 
 
Bromocriptine in addition to heart failure therapy should be considered because it has shown 
promising results with improved LV systolic function and clinical outcomes in several case series and in a 
small prospective proof‐of‐concept study.23 In the retrospective non‐randomized German PPCM Registry, 
treatment with beta‐blockers, ACE inhibitors, and bromocriptine (2.5 mg twice daily for 2 weeks 
followed by 2.5 mg per day for 6 weeks) was associated with favourable outcomes.
40
 A German study 
with 60 patients randomized to either short‐term or long‐term treatment with bromocriptine has 
terminated patient enrolment, and results will be available in the near future.
41
 Anticoagulation with 
heparin should be started in all patients with acute PPCM treated with bromocriptine and in those with 
severely reduced LV systolic function (LVEF ≤35%).24 
 
While diuretics should be tapered when possible after stabilization and when LVEF improves, ACE 
inhibitors, beta‐blockers, and MRAs should probably be given in guideline‐based dosages and not 
discontinued during the first 12 months after complete recovery of LV dimensions and systolic function. 
Earlier, stepwise discontinuation of heart failure therapy might be considered if both complete recovery of 
ventricular function and normal exercise response are achieved. Ivabradine should be given according to 
established indications. Furthermore, early treatment with ivabradine even before or in parallel with beta‐
blockers may be considered, as it appears to be safe and effective (Figure 3).
42
 
 
As relapses have been observed after recovery, tapering of the disease‐modifying heart failure drugs 
should be performed under close assessment of systolic function.
3
 
 
Joint cardiologic and obstetric management including counselling on the potential risk of PPCM 
recurrence with futures pregnancies is recommended. 
  
Prevention of sudden cardiac death 
Despite increasing knowledge about the epidemiology and pathophysiology of PPCM, mortality rates 
are not well described and may range from <5% up to 50%. It is assumed that about a quarter of deaths 
are caused by ventricular tachyarrhythmia, mostly occurring during the first 6 months, and therefore 
optimal management may prevent a substantial number of deaths.
4
 
 
Severely impaired ventricular function is associated with increased risk of life‐threatening 
arrhythmias. Current ESC guidelines for the treatment of heart failure recommend implantation of an ICD 
(implantable cardioverter defibrillator) for primary prevention in patients with symptomatic heart failure 
and LVEF ≤35% despite optimal pharmacological treatment or for secondary prevention in patients with 
documented ventricular arrhythmia causing haemodynamic instability.
37
 
 
In the context of PPCM, where young women with the potential for complete recovery of ventricular 
function are involved, decisions about implantation of an ICD should be taken with caution. After 
diagnosis of PPCM, clinicians are faced with the uncertainty about the subsequent evolution of 
ventricular function. Therefore, the related decision of whether to implant an ICD or not may be very 
challenging. 
 
Several publications reported recovery of LV function in at least 50% of patients within 6 months 
after diagnosis.
43,44
 However, a Turkish study reported delayed recovery (after 6 months) in a significant 
proportion of patients.
45 
A recent retrospective study from the USA showed complete recovery of LV 
function in 23% of patients and partial recovery in another 19% over a mean duration of 33 ± 21 months, 
confirming frequent delayed recovery over 6 months (83%).
46
 In this study, Afro‐American women 
showed lower rates of recovery compared with Caucasians, and post‐partum diagnosis was a predictor of 
good recovery. In a South African study, age and low LV end‐diastolic diameter were predictors of 
recovery, whereas LVEF was not.
47
 
 
In light of these data, early implantation of an ICD in patients with newly diagnosed PPCM is not 
appropriate. However, postponement of ICD implantation beyond the time point when further recovery of 
ventricular function is unlikely (6–12 months) exposes young mothers to an unacceptable risk of sudden 
cardiac death. 
 
Novel therapies, such as the wearable cardioverter‐defibrillator (WCD) (LifeVest®, Zoll, Pittsburgh, 
PA, USA) are an interesting alternative for the prevention of sudden cardiac death in the first months after 
diagnosis, until a definitive decision about ICD implantation can be made. A German study reported their 
experience with the WCD in patients with PPCM and severely reduced LV function. Seven out of nine 
women with PPCM and LVEF ≤35% received the WCD early after diagnosis. During a cumulative 
wearing period of 932 days, four adequate shocks were delivered for ventricular fibrillation in three 
patients without any inappropriate shock delivery within the first months of diagnosis.
4 
These results may 
suggest the prescription of the WCD due to the relevant risk for ventricular tachyarrhythmias for at least 
3–6 months after diagnosis to allow ‘protected’ recovery from severely reduced LV function.  
 
In patients without recovery despite 3–6 months on optimized heart failure therapy, a conventional 
recommendation for the primary prophylactic implantation of an ICD applies.
37,48
 In patients without 
LBBB or symptomatic sick sinus syndrome, single‐chamber ICDs are recommended. Subcutaneous ICDs 
(S‐ICDs) represent an alternative to transvenous systems in these young patients. Subcutaneous systems 
avoid intravascular leads and thus the potential complication of infections leading to endocarditis and lead 
extractions. On the other hand, subcutaneous systems can provide neither antitachycardia pacing (ATP) 
nor post‐shock pacing and therefore might not be the optimal choice for patients with recurrent 
ventricular tachycardia successfully terminated by ATP.  
  
In patients with heart failure, LVEF ≤35% despite optimal medical therapy for at least 3–6 months 
and LBBB, CRT is indicated, although no large studies have evaluated the value of CRT in patients with 
PPCM. Significant improvement of LV function in two PPCM patients undergoing CRT device 
implantation because of persistent symptomatic LV dysfunction was reported.
49
 
 
According to the current ESC guidelines on CRT, in patients with symptomatic heart failure, 
persistent LVEF ≤35%, and complete LBBB (QRS duration >130 ms), CRT should be offered; in patients 
with wide QRS complex with non‐LBBB morphology (QRS duration >150 ms), CRT may be 
considered.
48
 Although no data on device therapy in patients with PPCM exist, recommendations for the 
device therapy may be applied as in patients with dilated cardiomyopathy.  
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